This guideline was produced by the European region of the International Union against sexually transmitted infections (IUSTI) and refers to ascending infections in the female genital tract unrelated to delivery and surgery and does not include actinomyces-related infection.
BevanCDJohalBJMumtazG. Clinical, laparoscopic and microbiological findings in acute salpingitis: report on a United Kingdom cohort. Br J Obstet Gynaecol1995; 102: 407–414.
MorcosRFrostNHnatM. Laparoscopic versus clinical diagnosis of acute pelvic inflammatory disease. J Reprod Med1993; 38: 53–56.
4.
Recommendations arising from the 31st Study Group: The Prevention of Pelvic Infection. In: Templeton A (ed.) The prevention of pelvic infection. London: RCOG Press, 1996, pp.267–270.
5.
KamengaMCDe CockKMSt.LouisME. The impact of human immunodeficiency virus infection on pelvic inflammatory disease: a case-control study in Abidjan, Ivory Coast. Am J Obstet Gynecol1995; 172: 919–925.
6.
MugoNRKiehlbauchJANgutiR. Effect of human immunodeficiency virus-1 infection on treatment outcome of acute salpingitis. Obstet Gynecol2006; 107: 807–812.
7.
BukusiEACohenCRStevensCE. Effects of human immunodeficiency virus 1 infection on microbial origins of pelvic inflammatory disease and on efficacy of ambulatory oral therapy. Am J Obstet Gynecol1999; 181: 1374–1381.
8.
IrwinKLMoormanACO'SullivanMJ. Influence of human immunodeficiency virus infection on pelvic inflammatory disease. Obstet Gynecol2000; 95: 525–534.
9.
AltunyurtSDemirNPosaciC. A randomized controlled trial of coil removal prior to treatment of pelvic inflammatory disease. Eur J Obstetr Gynecol Reprod Biol2003; 107: 81–84.
10.
YudinMHHillierSLWiesenfeldHC. Vaginal polymorphonuclear leukocytes and bacterial vaginosis as markers for histologic endometritis among women without symptoms of pelvic inflammatory disease. Am J Obstet Gynecol2003; 188(2): 318–323.
11.
MiettinenAKHeinonenPKLaippalaP. Test performance of erythrocyte sedimentation rate and C- reactive protein in assessing the severity of acute pelvic inflammatory disease. Am J Obstet Gynecol1993; 169: 1143–1149.
12.
WestromL. Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industrialized countries. [Review] [74 refs]. Am J Obstet Gynecol1980; 138: 880–892.
13.
JudlinP. Current concepts in managing pelvic inflammatory disease. Curr Opin Infect Dis2010; 23: 83–87.
14.
HaggertyCLTottenPAAsteteSG. Failure of cefoxitin and doxycycline to eradicate endometrial Mycoplasma genitalium and the consequence for clinical cure of pelvic inflammatory disease. Sex Transm Infect2008; 84: 338–342.
15.
HillisSDJoesoefRMarchbanksPA. Delayed care of pelvic inflammatory disease as a risk factor for impaired fertility. Am J Obstet Gynecol1993; 168: 1503–1509.
16.
NessRBTrautmannGRichterHE. Effectiveness of treatment strategies of some women with pelvic inflammatory disease: A randomized trial. Obstet Gynecol2005; 106: 573–580.
17.
HemsellDLLittleBBFaroS. Comparison of three regimens recommended by the Centers for Disease Control and Prevention for the treatment of women hospitalized with acute pelvic inflammatory disease. Clin Infect Dis1994; 19: 720–727.
18.
MartensMGGordonSYarboroughDR. Multicenter randomized trial of ofloxacin versus cefoxitin and doxycycline in outpatient treatment of pelvic inflammatory disease. Ambulatory PID Research Group. Southern Med J1993; 86: 604–610.
WendelGDJrCoxSMBawdonRE. A randomized trial of ofloxacin versus cefoxitin and doxycycline in the outpatient treatment of acute salpingitis. Am J Obstet Gynecol1991; 164: 1390–1396.
21.
WitteEHPetersAASmitIB. A comparison of pefloxacin/metronidazole and doxycycline/metronidazole in the treatment of laparoscopically confirmed acute pelvic inflammatory disease. Eur J Obstet Gynecol Reprod Biol1993; 50: 153–158.
22.
JudlinPLiaoQLiuZ. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG: Int J Obstet Gynaecol2010; 117: 1475–1484.
23.
HeinonenPKTeisalaKMiettinenA. A comparison of ciprofloxacin with doxycycline plus metronidazole in the treatment of acute pelvic inflammatory disease. Scand J Infect Dis1989; 60: 66–73.
HeystekMJRossJDCStudy GroupPID. A randomised double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. Int J STD AIDS2009; 20: 690–695.
26.
RossJDCCronjeHSPaszkowskiT. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. Sex Transm Infect2006; 82: 446–451.
27.
HaggertyCLNessRBAmorteguiA. Endometritis does not predict reproductive morbidity after pelvic inflammatory disease. Am J Obstet Gynecol2003; 188: 141–148.
